Drug Trial Radar · NCT04093765
Mass Screening and Treatment for Reduction of Falciparum Malaria
Last checked: Nov 19, 2026Latest source record: Mar 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,542
Actual
Start
Nov 1, 2018
Primary completion
Dec 31, 2019
Study completion Dec 31, 2020
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 18, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In this project, the investigators aim at an operational research deployment of Ultrasensitive Rapid Diagnostic Test (URDT) -based Mass Screening and Treatment (MSAT) in the Malaria Elimination Task Force (METF) elimination program. This intervention will be tested in two types of setting. In group 1, MSAT will be used in a programmatic setting in order to decrease the reservoir of asymptomatic carriers in high incidence villages (following the same principles and objective as previously deployed MDA interventions). In group 2, the investigators take advantage of the lighter framework of MSAT to use it as a reactive intervention in order to respond to malaria outbreaks in low to intermediate incidence villages. The MSAT intervention will be preceded with community-level consent and community engagement (CE) activities. MSAT will be conducted over a period of approximately 1 week in each hamlet, village or group of villages, and will consist in administering a P. falciparum URDT to all individuals agreeing to participate. A limited subgroup (expected 5-25%) will be found positive and receive supervised treatment over 3 days for the standard regimen (DP to cure asexual stage infection + single low-dose primaquine to destroy gametocytes). After this intervention, the incidence of clinical falciparum episodes will be monitored by the village MP. In group 1, a comparison of the prevalence at baseline and 12 months after MSAT intervention will be performed through a second URDT survey, in addition to which both baseline and 12-month surveys will include the collection of a 200µL capillary blood sample for reference detection in the laboratory. The intervention will be evaluated primarily on its ability to reduce yearly cumulative incidence of clinical falciparum malaria compared to year before intervention. Additional evaluations of the impact of MSAT will include: in group 1, comparison of asymptomatic infection prevalence; and in group 2, modifications of the shape of the incidence curve following intervention. Funder: Wellcome Trust grant reference 106698/B/14/Z
Conditions
- Plasmodium Falciparum Malaria
Interventions
Ultrasensitive Rapid Diagnostic Test (URDT)Diagnostic test
Investigation will consist in 1 URDT. For P. falciparum URDT positive: * collection of 3x1cm dried blood spots on filter paper * administration of a supervised antimalarial treatment course to individuals for which a P. falciparum will have been detected by URDT. Specifically in group 1, a population list will be collected in each village prior to MSAT campaign and all participants will undergo: * collection of a 200 µL-aliquot of capillary blood for each participant to the screening during the MSAT intervention. * 1 URDT + collection of a 200µL-aliquot of capillary blood for each participant to the follow-up survey at M12.
AntimalarialsDrug
A safe, recommended treatment of P. falciparum malaria will be administered to URDT positive individuals based on participant's characteristics: * The standard regimen for participants without known antimalarial allergy, not pregnant and not breastfeeding, will be a 3-day supervised weight-adjusted DP course and a single low dose PMQ. The single low dose PMQ will be administered on the first day. * Pregnant women and in their 2nd or 3rd trimester, and breastfeeding mothers, will receive a DP course but no PMQ. * Pregnant women in their first trimester will receive an oral course of quinine+clindamycin (7 days). * Individuals with known drug allergy to piperaquine will be treated with AL (+/- sld PMQ as per their pregnancy/breastfeeding status) * Specific/complex cases will be assessed by a medic and referred to a health facility for treatment if necessary.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adjusted incidence rate ratio before/after MSATTime frame: 12 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shoklo Malaria Research Unit
Mae Sot, Changwat Tak, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.